These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 20538454)

  • 1. Phase I study of temozolomide combined with oral etoposide in children with recurrent or progressive medulloblastoma.
    Ruggiero A; Rizzo D; Attinà G; Lazzareschi I; Mastrangelo S; Maurizi P; Migliorati R; Bertolini P; Pastore M; Colosimo C; Riccardi R
    Eur J Cancer; 2010 Nov; 46(16):2943-9. PubMed ID: 20538454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of temozolomide combined with oral etoposide in children with malignant glial tumors.
    Ruggiero A; Rizzo D; Attinà G; Lazzareschi I; Maurizi P; Ridola V; Mastrangelo S; Migliorati R; Bertolini P; Colosimo C; Riccardi R
    J Neurooncol; 2013 Jul; 113(3):513-8. PubMed ID: 23666235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma.
    Korones DN; Benita-Weiss M; Coyle TE; Mechtler L; Bushunow P; Evans B; Reardon DA; Quinn JA; Friedman H
    Cancer; 2003 Apr; 97(8):1963-8. PubMed ID: 12673724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response of recurrent medulloblastoma to low-dose oral etoposide.
    Ashley DM; Meier L; Kerby T; Zalduondo FM; Friedman HS; Gajjar A; Kun L; Duffner PK; Smith S; Longee D
    J Clin Oncol; 1996 Jun; 14(6):1922-7. PubMed ID: 8656261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase 1 Trial of TPI 287 as a Single Agent and in Combination With Temozolomide in Patients with Refractory or Recurrent Neuroblastoma or Medulloblastoma.
    Mitchell D; Bergendahl G; Ferguson W; Roberts W; Higgins T; Ashikaga T; DeSarno M; Kaplan J; Kraveka J; Eslin D; Werff AV; Hanna GK; Sholler GL
    Pediatr Blood Cancer; 2016 Jan; 63(1):39-46. PubMed ID: 26235333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pilot trial of the rate of response, safety, and tolerability of temozolomide and oral VP-16 in patients with recurrent or treatment-induced malignant central nervous system tumors.
    Terasaki M; Bouffet E; Katsuki H; Fukushima S; Shigemori M
    Surg Neurol; 2008 Jan; 69(1):46-50. PubMed ID: 18054615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Temozolomide and oral VP-16 for children and young adults with recurrent or treatment-induced malignant gliomas.
    Korones DN; Smith A; Foreman N; Bouffet E
    Pediatr Blood Cancer; 2006 Jul; 47(1):37-41. PubMed ID: 16047359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma.
    Reardon DA; Quinn JA; Rich JN; Desjardins A; Vredenburgh J; Gururangan S; Sathornsumetee S; Badruddoja M; McLendon R; Provenzale J; Herndon JE; Dowell JM; Burkart JL; Newton HB; Friedman AH; Friedman HS
    Cancer; 2005 Oct; 104(7):1478-86. PubMed ID: 16088964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: a Children's Oncology Group Study.
    Bagatell R; Norris R; Ingle AM; Ahern C; Voss S; Fox E; Little AR; Weigel BJ; Adamson PC; Blaney S
    Pediatr Blood Cancer; 2014 May; 61(5):833-9. PubMed ID: 24249672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of O6-benzylguanine and temozolomide administered daily for 5 days to pediatric patients with solid tumors.
    Warren KE; Aikin AA; Libucha M; Widemann BC; Fox E; Packer RJ; Balis FM
    J Clin Oncol; 2005 Oct; 23(30):7646-53. PubMed ID: 16234526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Temozolomide is an active agent in children with recurrent medulloblastoma/primitive neuroectodermal tumor: an Italian multi-institutional phase II trial.
    Cefalo G; Massimino M; Ruggiero A; Barone G; Ridola V; Spreafico F; Potepan P; Abate ME; Mascarin M; Garrè ML; Perilongo G; Madon E; Colosimo C; Riccardi R
    Neuro Oncol; 2014 May; 16(5):748-53. PubMed ID: 24482446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma.
    Quinn JA; Jiang SX; Reardon DA; Desjardins A; Vredenburgh JJ; Rich JN; Gururangan S; Friedman AH; Bigner DD; Sampson JH; McLendon RE; Herndon JE; Walker A; Friedman HS
    Neuro Oncol; 2009 Oct; 11(5):556-61. PubMed ID: 19289491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic oral VP-16 for recurrent medulloblastoma.
    Chamberlain MC; Kormanik PA
    Pediatr Neurol; 1997 Oct; 17(3):230-4. PubMed ID: 9390699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma.
    Quinn JA; Jiang SX; Reardon DA; Desjardins A; Vredenburgh JJ; Gururangan S; Sampson JH; McLendon RE; Herndon JE; Friedman HS
    Cancer; 2009 Jul; 115(13):2964-70. PubMed ID: 19402172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of early recurrent medulloblastoma in children with cisplatin and etoposide: a preliminary report.
    Kudo H; Kokunai T; Kuwamura K; Tamaki N; Sawa H; Izawa I; Tatsumi S; Hamano S; Matsumoto S
    Childs Nerv Syst; 1992 May; 8(3):133-5. PubMed ID: 1611612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I, dose-escalation study of cyclical weekly oral temozolomide and weekly PEG-interferon alpha-2b in patients with refractory or advanced solid tumours.
    Coker SA; Dandamudi UB; Beelen AP; Crosby NA; Fisher JL; Obrocea M; Ernstoff MS; Lewis LD
    J Chemother; 2013 Dec; 25(6):362-8. PubMed ID: 24093213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose finding study of oral PSC 833 combined with weekly intravenous etoposide in children with relapsed or refractory solid tumours.
    Pein F; Pinkerton R; Berthaud P; Pritchard-Jones K; Dick G; Vassal G
    Eur J Cancer; 2007 Sep; 43(14):2074-81. PubMed ID: 17716890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of temozolomide and topotecan (TOTEM) in children with relapsed or refractory extracranial and central nervous system tumors including medulloblastoma with post hoc Bayesian analysis: A European ITCC study.
    Le Teuff G; Castaneda-Heredia A; Dufour C; Jaspan T; Calmon R; Devos A; McHugh K; Leblond P; Frappaz D; Aerts I; Zwaan CM; Ducassou S; Chastagner P; Verschuur A; Corradini N; Casanova M; Rubie H; Riccardi R; Le Deley MC; Vassal G; Geoerger B;
    Pediatr Blood Cancer; 2020 Jan; 67(1):e28032. PubMed ID: 31595663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 1 study of an oxaliplatin and etoposide regimen in pediatric patients with recurrent solid tumors.
    McGregor LM; Spunt SL; Santana VM; Stewart CF; Ward DA; Watkins A; Laningham FH; Ivy P; Furman WL; Fouladi M
    Cancer; 2009 Feb; 115(3):655-64. PubMed ID: 19117350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study of topotecan in combination with temozolomide (TOTEM) in relapsed or refractory paediatric solid tumours.
    Rubie H; Geoerger B; Frappaz D; Schmitt A; Leblond P; Ndiaye A; Aerts I; Le Deley MC; Gentet JC; Paci A; Chastagner P; Dias N; Djafari L; Pasquet M; Chatelut E; Landman-Parker J; Corradini N; Vassal G
    Eur J Cancer; 2010 Oct; 46(15):2763-70. PubMed ID: 20558056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.